ClinicalTrials.gg
CompletedNCT01448200Updated Nov 16, 2012

A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1

A Phase 1 interventional study of PPI-668 and Placebo in Hepatitis C, Chronic, sponsored by Presidio Pharmaceuticals, Inc.. Completed at 7 sites in 3 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-11-16.

Sponsored by Presidio Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 256 studies in Hepatitis C, Chronic with a site in United States — none open to participants now, 3 under way, none of them phase 3. Hepatitis C, Chronic · United States.

Enrollment
113th of 220
82 · median 89
Started
2011
with 32 others
Phase 1
31 of 256
none open now
Registered
142nd of 256
by date

Among the 256 studies in Hepatitis C, Chronic with a site in United States, this one is the 113th largest by enrollment of the 220 interventional ones that give a count, is one of 33 that started in 2011, is one of 31 in phase 1, and was the 142nd registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 256 studies in Hepatitis C, Chronic with a site in United States is open now. The open studies under Hepatitis C, Chronic, anywhere →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 256 studies in Hepatitis C, Chronic with a site in United States as a file.
02

Study summary

PPI-668 is an antiviral agent (a hepatitis C NS5A inhibitor) that is being developed as a potential treatment for hepatitis C virus infection. This study is being done to assess the safety and tolerance of PPI-668 when given to healthy volunteers for up to 5 days (Part I of the study) and to hepatitis C patients for up to 3 days (Part II). In addition, the study will assess how much PPI-668 is absorbed into the bloodstream. In Part II, the effect of PPI-668 on the amount of hepatitis C virus in patients' bloodstream (serum HCV RNA levels) also will be assessed.

03

Conditions studied

  • Hepatitis C, Chronic

Keywords

  • hepatitis C
  • NS5A inhibitor
  • Phase 1
  • genotype-1
  • genotype-2
  • genotype-3
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

In order to participate in the study, volunteers for Part I and patients for Part II must meet all of the following key entry criteria, as well as other entry criteria specified in the full protocol:

Key Inclusion Criteria

  1. Male or female, between 18 and 65 years of age. Female patients must be surgically sterile or two years .
  2. (BMI) 18 - 35 kg/m2
  3. In good health, in the judgment of the Principal Investigator
  4. Able and willing to comply with all protocol requirements and to sign an .

Key Exclusion Criteria:

  1. Seropositive for antibody, or surface antigen (HBsAg) at Screen. Volunteer subjects for Part I must also be negative for antibody.
  2. Any medical condition that may interfere with the absorption, distribution or elimination of study drug (PPI-668), or with the clinical and laboratory assessments in this study.
  3. Poorly controlled or unstable hypertension; or sustained systolic BP > 150 or diastolic BP > 95 at Screen.
  4. History of Diabetes Mellitus treated with insulin or hypoglycemic agents
  5. History of alcohol abuse or illicit drug use which, in the investigator's judgment, could interfere with a patient's compliance, with the protocol requirements or with the safety or efficacy assessments of the study
  6. History of unless the malignancy has been in complete remission and without additional medical or surgical interventions during the preceding three years
  7. No laboratory abnormalities at Screen for healthy volunteers in Part I. For Screen laboratory parameters for HCV patients in Part II, refer to the 'Additional Criteria for HCV Patients' below.

Additional Key Entry Criteria for HCV patients (Part II):

  1. Clinical diagnosis of chronic hepatitis C, documented by:

    1. Clinical findings compatible with chronic hepatitis C, and absence of other known liver disease
    2. Seropositive for HCV antibody or HCV RNA at least once previously, and at Screen
    3. Serum HCV RNA > 5 log10 IU/mL at Screen, by the PCR assay at the central study laboratory
    4. HCV genotype-1 (1a or 1b, or non-subtypable genotype-1), or HCV genotype-2a or genotype-3a
  2. must be \<5 x at screen
  3. No previous treatment with interferon, pegIFN, or ribavirin for genotype-1 patients
  4. No history of signs or symptoms of decompensated liver disease
  5. Any of the following laboratory values at Screening will be exclusionary for study participation:

    • \<11 g/dL in women or 12 g/dL in men.
    • White blood cell count \< 4,000/mm3.
    • (ANC) \< 1800 per mm3.
    • count \< 100,000 per mm3.
    • Serum creatinine >ULN at the central study laboratory.
    • Serum albumin \< 3.4 g/dL.
    • Total > 2.0 mg/dL
    • Clinically significant abnormality in the (ECGs) at Screen
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Part I: single dose escalation in healthy volunteers

    There will be three sequential single dose cohorts: Cohort A: PPI-668 dose D1 or placebo Cohort B: PPI-668 dose D2 or placebo Cohort C: PPI-668 dose D3 or placebo

    Drug: PPI-668 · Drug: Placebo

  • Experimental
    Part I: multiple dose administration to healthy volunteers

    Upon completion of the single dose escalation phase, an additional cohort will receive repeat doses: Cohort D: highest well-tolerated dose from Cohorts A-C or placebo once daily for five days

    Drug: PPI-668 · Drug: Placebo

  • Experimental
    Part II: multiple dose escalation in HCV subjects

    Upon completion of Part I, there will be 3, and potentially 4, sequential cohorts of HCV patients: Cohort E (genotype-1): PPI-668 dose E1 or placebo Cohort F (genotype-1): PPI-668 dose E2 or placebo Cohort G (genotype-1): PPI-668 dose E3 or placebo Cohort H (genotype-1): if necessary for dose-response assessment; dose to be determined Cohort I (genotype-2 or -3): PPI-668 dose E4 or placebo

    Drug: PPI-668 · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability, as measured by clinical adverse events and laboratory assessments

    Time frame: Part I, up to day 12; and Part II, up to day 17

Secondary outcomes

  1. PPI-668 plasma levels

    Time frame: Part I, up to day 12; and Part II, up to day 17

  2. serum HCV RNA levels

    Time frame: Part II, up to day 17

07

Study locations

7 sites
  • Investigational site
    Costa Mesa, California, United States
  • Investigational site
    Sacramento, California, United States
  • Investigational site
    San Francisco, California, United States
  • Investigational Site
    San Antonio, Texas, United States
  • Investigational site
    Canberra, Australia
  • Investigational site
    Auckland, New Zealand
  • Investigational site
    Christchurch, New Zealand
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2011
First posted
Oct 7, 2011
Start
Oct 2011
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Last update
Nov 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01448200
Lead sponsor
Presidio Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Oct 7, 2011
Start date
Oct 2011
Primary completion
Nov 2012
Completion
Nov 2012
Last update
Nov 16, 2012

Study contacts

Nathaniel Brown, M.D.
study director · Presidio Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravidasvir

Start the discussion